Serdia Pharma bags CDSCO approval for anti-diabetic FDC of extended-release Gliclazide 60mg plus Metformin 1000mg tablet - Video
|
Overview
In a significant development, Serdia Pharmaceuticals (India) Pvt. Ltd. has got approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market an anti-diabetic fixed-dose combination uncoated bilayer tablet comprising Gliclazide 60mg (as extended-release) plus Metformin Hydrochloride IP 1000mg (as extended-release) tablet.
Gliclazide plus Metformin is a combination of two antidiabetic medicines, used in the treatment of type 2 diabetes mellitus (T2DM). It improves blood glucose levels in adults when taken along with proper diet and regular exercise.
For more information, check out the full story on the link below:
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
